AcclaimIP-ad

Match Document Document Title Score
4975426 Cough/cold mixtures comprising non-sedating antihistamine drugs  
Pharmaceutical compositions and methods of using same comprising aspirin, sodium salicylate, salicylamide or acetaminophen, in combination with a non-sedating antihistamine and optionally one or...
145
US20070292498 Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers  
Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent, a sleep aid and acetaminophen, ibuprofen, aspirin or naproxen are described. Methods are described for...
145
2056208 Acetyl-salicylic acid composition  
This invention relates to an improved acetylsalicylic acid composition, and more particularly to a stable solution of acetyl-salicylic acid, i. e. "aspirin", which term is hereinafter employed for...
144
US20100286100 Method and composition to improve absorption of therapeutic agents  
A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally...
143
US20170073413 METHODS AND COMPOSITIONS FOR TREATING SIGLEC-8 ASSOCIATED DISEASES  
The invention provides methods and compositions for the prevention and treatment of Siglec-8 associated diseases such as chronic rhino sinusitis with concomitant asthma and aspirin-exacerbated...
142
US20050101658 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events  
Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a...
142
US20100286099 INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE  
A water-soluble aspirin-theanine cocrystal composition which includes a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer associated with the quantity of acetylsalicylic...
142
6511968 Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions  
The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis,...
141
US20090062240 Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate  
The present invention relates to a novel pharmaceutical combination, containing an inhibitor of platelet aggregation and a fÊbrate, where the inhibitor of platelet aggregation is preferably either...
141
US20080287403 USE OF INHIBITORS OF THE RENIN-ANGIOTENSIN SYSTEM IN THE PREVENTION OF CARDIOVASCULAR EVENTS  
Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a...
141
US20020166835 Cap with flip-top compartment  
A cap (10) for use with a container, such as a bottle, tube, or can, wherein the cap (10) provides a flip-top storage compartment (16) operable to store one or more small objects in close...
141
US20070264370 Composition and methods for the treatment of joint pain using Angelica gigas Nakai extract and powder as combined with Glucosamine Sulfate, or Chondroitin Sulfate and HCL, or MSM, or aspirin, or Celedrin, and as combinations thereof in powder, pill, capsule, spray, liquid, and gelcap form  
The present invention relates to composition comprising dry powder of decursinol, decursin, and their related derivates isolated from the roots of Angelica gigas Nakai (Korean Angelica) plant and...
141
7029663 Stable ointment containing acetylsalicylic acid  
A substantially anhydrous stable ointment containing Aspirin which is characterized in using gelation hydrocarbon and/or vaseline as a base. The ointment is superior in stability and can be stored...
141
4970202 Pharmaceutical compositions containing non-steroidal anti-inflammatory drugs  
A pharmaceutical composition for treating an inflammatory condition contains a non-steroidal anti-inflammatory drug (NSAID) and a physiologically acceptable aromatic hydroxysulphonic acid. The two...
140
US20070259958 Prevention of Neutrophil Recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20030069435 PREVENTION OF NEUTROPHIL RECRUITMENT  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20120010286 PREVENTION OF NEUTROPHIL RECRUITMENT  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20030055275 Prevention of neutrophil recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20100048702 PREVENTION OF NEUTROPHIL RECRUITMENT  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
6960674 Prevention of neutrophil recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20050192350 Prevention of neutrophil recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20030191332 Prevention of neutrophil recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
US20080064747 Prevention of Neutrophil Recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
8022105 Prevention of neutrophil recruitment  
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.
139
7029701 Composition for the treatment and prevention of ischemic events  
The invention relates to pharmaceutical compositions comprising omeprazole and aspirin wherein the combination is useful for the treatment and prevention of cardiovascular events including heart...
137
US20050147667 Method of ensuring patient identification of prescribed drug and quantity for prescribed purpose and improved self-identifying drug appearance  
A technique for assuring patient use of the correct drug pill for a prescribed treatment of a particular body organ or part, involving shaping the pill to have an appearance resembling such body...
136
4080446 Suppression of thrombocyte aggregation  
2-(4,5-BIS-P-CHLOROPHENYLOXAZOL-2-YL-MERCAPTO)-PROPIONIC ACID AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS IS USEFUL FOR SUPPRESSING AGGREGATION OF THROMBOCYTES, PARTICULARLY WHEN ADMINISTERED IN...
136
7833793 Method and device for monitoring inhibition of platelet function  
The invention provides a method of monitoring the response of platelets to a COX1 inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood treated with a COX1...
136
10098913 Composition of stem cells having highly expressed FAS ligand  
This disclosure relates in general to a stem cell treatment. This disclosure further relates to a stem cell treatment using a composition comprising stem cells having highly expressed Fas-L. This...
136
US20080319355 Ischemic stroke therapy  
A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and...
135
US20100120727 Eflornithine Prodrugs, Conjugates and Salts, and Methods of Use Thereof  
In one aspect, the present invention provides a composition of a covalent conjugate of an eflornithine analog with an anti-inflammatory drug. In another aspect, the present invention provides a...
135
6696485 Procyanidin and cyclo-oxygenase modulator compositions  
This invention relates to compositions comprising a cyclo-oxygenase modulator in combination with cocoa procyanidin monomers and/or oligomers, wherein the cyclo-oxygenase modulator is a...
135
US20150328162 PHARMACEUTICAL PREPARATIONS  
The present invention relates to an improved pharmaceutical preparation comprising a dosage form of an active ingredient such as aspirin, acetaminophen, ibuprofen, naproxen sodium salt, or other...
134
US20160107002 Ischemic Stroke Therapy  
A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and...
132
US20130122098 Method and composition to improve absorption of therapeutic agents  
A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally...
130
US20100098676 SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS  
Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits...
130
5871766 Beta-carotene vitamin E therapy for inhibition of major vascular events  
This invention is directed to a method for inhibiting the occurrence of a major vascular event in a subject whereby a subject is administered beta-carotene and/or vitamin E, either alone or in...
130
6485747 Coated active tablet(s)  
A tablet coating useful for coating an active selected from the group consisting of aspirin, ibuprofen, naproxin sodium, acetaminophen, celecoxib, sildenafil citrate, alendronate sodium, an...
130
US20040087645 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events  
Use of an inhibitor of the renin-angiotensin system or a pharmaceutically acceptable derivative thereof, optionally together with an other antihypertensive, a cholesterol lowering agent, a...
130
6932988 Kit and method for migraine headache treatment  
A kit and method for treating migraine headaches comprising the preparing of an oral composition containing at least two bags of black pekoe tea brewed in approximately three ounces of boiling...
129
4512981 Method of treating inflammation using inosiplex  
Inosiplex has been found to be useful as an anti-inflammatory agent, e.g., to treat rheumatoid arthritis. There is no need to employ known anti-inflammatory agents, e.g., indomethacin or aspirin,...
128
US20110098256 Method for making and using a topical dermatological solution  
A novel method for making and using topical dermatological solution for external use which is effective in treating dermatological disorders. The methods include administering a therapeutically...
127
7622502 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The...
126
7622501 Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H)-furanones useful in the treatment of cyclooxygenase-2 mediated diseases, Formula...
126
8841129 Method for monitoring inhibition of platelet function  
The invention provides a method of monitoring the response of platelets to a cyclooxygenase-1 (COX1) inhibitor such as aspirin. The method involves collecting platelet-containing mammalian blood...
126
US20080227758 Nitric Oxide Releasing Prodrugs of Diaryl-2-(5h)-Furanones as Cyclooxygenase-2 Inhibitors  
The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The...
126
7119068 Methods of screening for compounds that modulate TAFIa activity, compounds, and methods of using the compounds  
Provided are methods of screening compounds for any aspirin-related activity other than TAFI inhibition, and also for non-inhibition of TAFI. Compounds identified by the screening methods can be...
126
US20090048216 INTRAVENOUS AND ORAL DOSING OF A DIRECT-ACTING AND REVERSIBLE P2Y12 INHIBITOR  
The invention provides methods and compositions for rapid and reversible inhibition of platelet aggregation in human subjects in need thereof by administering compounds of the formula: alone or in...
124
US20050142216 Method for reversing Alzheimer dementia  
A method of reducing the effects of Alzheimer's Dementia can include a step of administering amoxicillin and Vitamin B12 to a patient experiencing Alzheimer Dementia. Another step of the method...
123
3911124 Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors  
There is disclosed concomitant systemic administration of prostaglandins of the PGB-type, for example, PGB2, and a prostaglandin synthetase inhibitor, for example, indomethacin, aspirin, or...
122

Search
« search again